{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Li L"],"funding":["Provincial Administration of Traditional Chinese Medicine Resource","National Natural Science Foundation of China","The National Multidisciplinary Innovation Team Project of Traditional Chinese Medicine: Multi-dimensional Evaluation and Multidisciplinary Innovation Team of Southwest Traditional Chinese Medicine Resources"],"pagination":["e2409711"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12376669"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["12(30)"],"pubmed_abstract":["Ulcerative colitis (UC) is a chronic disease. A significant challenge for the management of UC is to achieve delivery of drugs to the multi-layer colonic barriers, as existing drugs are difficult to penetrate these depths. In this study, a novel drug delivery system using yeast cell wall microparticles (YPs) are developed to co-encapsulate Bacillus subtilis (BS) and Rhein (Rh) termed Rh-YBS. This system specifically targets colonic microfold cells, enabling direct delivery of BS to the colonic submucosa. Additionally, Rh enhances BS colonization in the submucosa through floral regulation. Studies indicate that Rh-YBS can effectively reach and proliferate within the submucosa in vivo. In a DSS-induced UC mouse model, Rh-YBS stimulates the CGRP-related neural pathway; BS activation in the su"],"journal":["Advanced science (Weinheim, Baden-Wurttemberg, Germany)"],"pubmed_title":["Colonic Submucosa Targeted Delivery of Probiotic and Rhein for Ulcerative Colitis Treatment."],"pmcid":["PMC12376669"],"funding_grant_id":["2024ZD04","82274366","ZYYCXTD796D-202209 Sichuan","2023ZD01","82405052","82474343"],"pubmed_authors":["Liu H","Wu K","Zhang F","Liu J","Zhang M","He L","Sun X","Li L","Gao F","Tu H","He S","Dai L","You J","Fu C","Ye N","Wang Q","Lin D","Huang X","Tao S","Du H","Wang Y","Lin M"],"additional_accession":[]},"is_claimable":false,"name":"Colonic Submucosa Targeted Delivery of Probiotic and Rhein for Ulcerative Colitis Treatment.","description":"Ulcerative colitis (UC) is a chronic disease. A significant challenge for the management of UC is to achieve delivery of drugs to the multi-layer colonic barriers, as existing drugs are difficult to penetrate these depths. In this study, a novel drug delivery system using yeast cell wall microparticles (YPs) are developed to co-encapsulate Bacillus subtilis (BS) and Rhein (Rh) termed Rh-YBS. This system specifically targets colonic microfold cells, enabling direct delivery of BS to the colonic submucosa. Additionally, Rh enhances BS colonization in the submucosa through floral regulation. Studies indicate that Rh-YBS can effectively reach and proliferate within the submucosa in vivo. In a DSS-induced UC mouse model, Rh-YBS stimulates the CGRP-related neural pathway; BS activation in the su","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Aug","modification":"2026-05-09T17:49:15.824Z","creation":"2026-04-08T01:08:26.183Z"},"accession":"S-EPMC12376669","cross_references":{"pubmed":["40344311"],"doi":["10.1002/advs.202409711"]}}